Background: EndoTAG-1, composed of paclitaxel embedded in liposomal membranes targeting tumor endothelial cells, was evaluated for safety and efficacy in advanced triple-negative breast cancer (TNBC). .4, and 3.7 months, respectively. After complete treatment (week 41 analysis), median overall survival (OS) was 13.0, 11.9, and 13.1 months for the modified Intention-to-Treat (ITT) population and 15.1, 12.5, and 8.9 months for the per-protocol population, respectively. The clinical benefit rate was 53%, 31%, and 36% for the treatment groups. Safety analysis revealed known toxicities of the drugs with slight increases of grade 3/4 neutropenia on combination therapy. NCT00448305.
introduction Triple-negative breast cancer (TNBC) accounts for ∼15% of all BC types and is characterized by the lack of estrogen receptor and progesterone receptor expression and also the lack of human epidermal growth factor receptor 2 (HER2) overexpression [1] . Since efforts to develop targeted drugs have failed to date [2] , chemotherapy based on existing cytotoxic agents is currently the standard treatment of TNBC [1, 3] . Although clinical data indicate a high initial sensitivity of triple-negative tumors to neoadjuvant [4] and adjuvant [5] chemotherapy, clinical outcomes remain poor compared with other BC subtypes. TNBC patients have high rates of local recurrences or distant metastases, and overall survival is decreased [3, 6] .
Taxanes are one of the most active and widely used classes of cytotoxic agents in BC treatment with efficacy in neoadjuvant [7] , adjuvant [8] , and metastatic [9] settings. Both in advanced BC [10] and in operable TNBC [11] , dose-dense weekly or biweekly taxanes achieved greater efficacy than larger doses given less often. EndoTAG™-1 is a cationic liposome formulation of lipid-embedded paclitaxel, targeting paclitaxel to negatively charged, activated tumor endothelial cells [12] . Binding and internalization of cationic liposomes were demonstrated in various experimental studies [13, 14] . Via leaky tumor vasculature, chemotherapeutic agents might have easier access to tumor cells. Indeed, antitumor activity was highest when EndoTAG™-1 was administered in combination with other chemotherapeutics [15, 16] . In several phase I and II studies, EndoTAG™-1 was well tolerated with predictable and manageable adverse events (AEs) [15, 17] . In addition to infusion-associated reactions, hematological toxicities typical for this class of cytotoxic agents were observed.
In the present study, EndoTAG™-1 plus paclitaxel, EndoTAG™-1 monotherapy, and paclitaxel monotherapy were investigated for a progression-free survival (PFS) rate of >30% and other safety and efficacy parameters.
patients and methods

patient selection
Patients with locally relapsed and/or metastatic TNBC were enrolled. Triple negativity was confirmed centrally during the first weeks of study participation. Eligibility criteria included ≥6 months after the end of any previous taxane-containing chemotherapy, ≥1 measurable tumor lesion (RECIST [18] ), Eastern Cooperative Oncology Group (ECOG) status ≤2, and adequate organ function. Patients were excluded if they had >1 prior chemotherapy for advanced disease. After approval by the sites' review boards, the study was conducted according to the Declaration of Helsinki and ICH-GCP guidelines. All patients gave informed consent before any study-related procedures.
study design and treatment
In this open-label, randomized, controlled phase II trial, patients were randomly assigned to weekly EndoTAG™-1 (22 mg/m 2 ) plus paclitaxel (70 mg/ m 2 ) (group 1), EndoTAG™-1 (44 mg/m 2 twice a week; total dose/week: 88 mg/m 2 ) (group 2), or weekly paclitaxel (90 mg/m 2 ) (group 3). Doses and regimens of EndoTAG™-1 were established based on existing trial data [15, 17] . Each cycle comprised 3 weeks of treatment followed by a week of rest. Patients were treated for four cycles (16 weeks, first treatment phase) unless documented disease progression (PD), unacceptable toxicity, or patient refusal. Responders of the EndoTAG™-1-based groups had the option to continue (additional treatment phase). Premedication with dexamethasone was mandatory in groups 1 and 3 before administration of paclitaxel. All patients were followed up for progression and survival.
Primary end point was a PFS rate at week 16, defined as the rate of all treated patients alive and without progression 16 weeks after treatment start based on results of central image evaluation; results of local evaluations were considered supportive.
assessments
Tumor responses were evaluated according to RECIST [18] at week 16 (central and local evaluation) and week 41 (local evaluation). Using local evaluation at week 41, best overall response, defined as complete response (CR), partial response (PR), or stable disease (SD) at any time, and clinical benefit rate, defined as CR/PR at any time or SD at ≥6 months, were determined.
Time-to-event parameters [PFS and overall survival (OS)] were defined as time from randomization to date of event (PD and/or death). PFS and OS rates at week 16 were based on the rate of patients with non-PD and patients alive 16 weeks after randomization, respectively.
Pain was assessed by Visual Analogue Scales and quality of life (QoL) by EORTC QLQ-C30 questionnaires. AEs were recorded at each visit and classified according to the National Cancer Institute-Common Terminology Criteria (NCI-CTCAE) version 3.0.
statistical analysis
The week 16 analysis for primary end point was carried out when the last randomized patient finished the first treatment phase or discontinued, whatever occurred earlier. The week 41 analysis was carried out when the last randomized patient reached week 41 or discontinued, whatever occurred earlier. The trial was exploratory and not powered for any between-group comparisons.
The hypothesis for both EndoTAG™-1 treatment groups was H 0 : PFS rate at week 16 ≤30% versus H 1 : PFS rate at week 16 ≥50%. Point estimates and the lower limits of exact one-sided 95% confidence intervals (95% CIs) were calculated. For groups 1 and 2, a sample size of 54 patients each was considered sufficient to reject a PFS rate of 30% (H 0 ) with a power of 90% if the true rate was 50% (H 1 ). For group 3, no power calculations were carried out. In total, 135 patients were randomly assigned to the treatment groups at a ratio of 2 : 2 : 1.
Continuous variables were summarized using standard summary statistics as appropriate (n, mean, standard deviation, median, minimum, and maximum). Statistical methods included frequency counts and percentages for categorical variables, point estimates and 95% CIs for survival rates, and Kaplan-Meier estimates and plots for time-to-event data.
All randomized patients who were treated at least once with study medication were summarized in the modified ITT (mITT) population and the safety population. The per-protocol (PP) population consisted of all treated patients without any major protocol violations. Efficacy end points were analyzed based on the mITT population, the PP population, and a retrospectively defined subgroup with centrally confirmed TNBC, ECOG 0/1 at baseline and receiving study medication as first-line treatment of advanced disease. Safety variables were evaluated based on the safety population.
results
patient characteristics
One hundred and forty-three patients with advanced TNBC were randomized at 33 centers in six countries. Three patients did not start therapy because of pretreatment AEs. One hundred and forty (100%) patients were included in the efficacy (mITT) and safety population, 124 (89%) in the PP population, and 119 (85%) in the subgroup population. Baseline characteristics were well balanced between treatment groups (Table 1) , except for a higher number of Asian patients (23%) on EndoTAG™-1 monotherapy. At randomization, 17% of patients had local relapse and 89% metastatic disease. Approximately 30% of patients lacked previous adjuvant chemotherapy, the majority being recruited at Ukraine.
treatments
Treatment with study medication started about 35 months after first diagnosis (Table 1) . Thirty-six (65.5%) patients on combination therapy completed the first treatment phase, 26 (46%) on EndoTAG™-1, and 16 (57%) on paclitaxel ( Figure 1 ). Discontinuations were predominantly due to PD. On EndoTAG™-1 monotherapy, 10 (17.5%) patients withdrew consent, presumably owing to the burden of having two infusions/week. During the first treatment phase, median duration of overall treatment was 99, 85, and 98 days for groups 1, 2, and 3, At week 16, PR was reported for 11 (25%) patients on combination therapy, 2 (5%) on EndoTAG™-1, and 9 (38%) on paclitaxel. None of the patients achieved CR. SD was observed in 15 (34%), 11 (29%), and 3 (13%) patients in groups 1, 2, and 3, respectively (Table 3 , central evaluation).
At week 41, local evaluation revealed objective responses in 22 (45%) patients on combination therapy, 12 (25%) on EndoTAG™-1, and 8 (32%) on paclitaxel. SD was observed in 17 (35%), 20 (41%), and 9 (36%) patients, resulting in a best overall response in 39 (80%), 32 (65%), and 17 (68%) patients of groups 1, 2, and 3, respectively. Accordingly, 26 (53%), 15 (31%), and 9 (36%) patients achieved overall clinical benefit (Table 3) .
Median OS (mITT) was 13.0, 11.9, and 13.1 months for groups 1, 2, and 3, respectively (Figure 2A, including 95% CIs) . The PP population showed a median OS of 15.1, 12.5, and 8.9 months, and the subgroup population a median OS of 17.8, 11.9, and 10.1 months.
Median PFS (central evaluation, week 16 analysis) reached 4.2, 3.4, and 3.7 months for groups 1, 2, and 3, respectively. Final analysis (local evaluation, week 41) revealed a median PFS of 3.7, 3.0, and 3.5 months (mITT, Figure 2B , including 95% CIs). The PP population showed a median PFS of 3.9, 3.5, and 3.2 months and the subgroup population a median PFS of 6.6, 2.6, and 3.5 months.
Assessment of pain revealed small differences between the treatment groups and high interpatient variations. There were no noteworthy differences in QoL. Change from baseline during treatment in QLQ-C30 global health status was −0.3, −4.2, and −2.1 in groups 1, 2, and 3, respectively.
safety results
Treatment-emergent AEs were reported in nearly all patients (93%-100%), with ∼20% being serious. AEs resulting in permanent discontinuation of study medication were reported in 5 (9.1%) patients on combination therapy, 10 (17.5%) on EndoTAG™-1, and 3 (10.7%) on paclitaxel. The increased number of discontinuations on EndoTAG™-1 monotherapy was predominantly due to hypersensitivity in 4 (7.0%) patients and fatigue and dyspnea in 2 (3.5%) patients each. Systemic corticosteroids, predominantly dexamethasone, were administered in 42 (76.4%), 34 (59.6%), and 20 (71.4%) patients of groups 1, 2, and 3, respectively.
During the first treatment phase, two patients on combination therapy and one patient on paclitaxel monotherapy died due to AEs, but deaths were considered not related to study medication. In addition, one patient of the EndoTAG™-1 monotherapy group died because of severe dyspnea due to PD; death was considered unlikely to be related.
Safety analysis revealed the known toxicities of the study drugs (Table 4) . Manageable NCI-CTC grade 3/4 neutropenia was the major AE related to the combination of EndoTAG™-1 and paclitaxel. Infusion-related reactions (pyrexia and chills) occurred more frequently and severely in EndoTAG™-1-based treatment 
discussion
Different paclitaxel-based regimens with cumulative doses of ∼90 mg/m 2 paclitaxel/week were evaluated in advanced TNBC. Although differences were limited, a trend for higher antitumor activity was observed on combination therapy, indicating a possible synergistic activity of EndoTAG™-1 and paclitaxel and supporting the proposed mechanism of action of EndoTAG™-1. Response rates on paclitaxel in the present study were similar to rates of 30%-60% described in previous studies treating patients with metastatic breast cancer (mBC) [2, 3] . Few studies were conducted in metastatic TNBC evaluating other treatment options such as carboplatin/gemcitabine [19] , iniparib plus carboplatin/gemcitabine [20] , gemcitabine/paclitaxel [21] , ixabepilone/capecitabine [22] , and cisplatin/gemcitabine [23] . In summary, these treatments revealed response rates of 23%-36%, median PFS of 4.1-6.0 months, and median OS of 11-12 months. With responses of 45%, PFS of 3.7 months, and OS of 13.0 months, the combination of EndoTAG™-1/paclitaxel compares well to these results. Nevertheless, data still represent a dismal outcome for patients with advanced TNBC.
A meta-analysis of trials with bevacizumab plus first-line chemotherapy in TNBC revealed responses of 42%, median PFS of 8.1 months, and median OS of 18.9 months not statistically different from the chemotherapy-only cohort [24] . During the first-line treatment of HER2-negative BC, combinations of bevacizumab and nab-paclitaxel achieved responses of 30%-46% and PFS of 7.7-9.2 months [25, 26] . Addition of gemcitabine to this combination showed responses of 76%, PFS of 10.4 months, and OS of 18 months [27] . With PFS of 6.6 months and OS of 17.8 months on EndoTAG™-1/paclitaxel combination therapy, similar results were obtained in the present study for a comparable subgroup (TNBC, ECOG 0/1, and first-line), presumably representing the most promising patient population for vascular-targeting agents such as EndoTAG™-1.
AEs of the trial were consistent with the known safety profiles of EndoTAG™-1 and paclitaxel. Higher frequencies (22%) of severe neutropenia were observed on combination, but different use of steroid premedication in the treatment groups may have affected these results. However, no significant neutropenia-related events were observed on either treatment. Trials in mBC patients using nab-paclitaxel, docetaxel, larotaxel, or ixabepilone reported 5%-82% of severe neutropenia [28] .
For peripheral sensory neuropathy, there was no potentiating effect observed on EndoTAG™-1/paclitaxel combination. None of the events was grade 3/4, comparing favorably to studies reporting 2%-22% of severe neuropathies for different chemotherapeutics [28] . Infusion-related reactions ( pyrexia and chills) were most frequent on EndoTAG™-1-based treatments, but severity was predominantly mild/moderate. Similar reactions during and after infusion of EndoTAG™-1 were observed in previous studies [15] .
In conclusion, treatment of patients with EndoTAG™-1/ paclitaxel combination therapy demonstrated potential antitumor activity in advanced TNBC. Treatment was well tolerated with manageable AEs. Subgroup analysis indicated that EndoTAG™-1/ paclitaxel combination may be an efficacious and less toxic 
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